RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; controlled, double-blind, randomized study of BAY 59-7939 in the prevention of VTE in subjects undergoing elective total knee replacement The objective is to assess the efficacy and safety of BAY 59-7939 10 mg once daily dosing in prevention of VTE in men and women aged 18 years or above undergoing elective total knee replacement.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Multicenter, open-label, randomized study to evaluate inhibition of ovulation of two transdermal patch formulations containing 0.55 mg ethinylestradiol and either 1.05 or 2.1 mg gestodene in healthy young female volunteers over a period of 3 treatment cycles The primary objective of this study is to evaluate the inhibition of ovulation in treatment cycles 2 and 3 administration of two different patches containing ethinylestradiol (EE) / gestodene (GSD) fo...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and safety of finerenone in subjects with chronic heart failure at high risk of recurrent heart failure decompensation A finerenon hatásossága és biztonságossága olyan krónikus szívelégtelen betegek esetén, akiknél magas a visszatérő szívelégtelenség-dekompenzáció kockázata Demonstrate the superiority of finerenone to eplerenone in delaying time to first occurrence of the composite endpoint, defined as cardiovascular (CV) death or hospitalization for heart failure (HF), ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles The primary objective of this study is to evaluate the inhibition of ovulation in treatment cycles 2 and 3 after dermal application of 3 different patch formulations containing ethinylestradiol (EE) /...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism For the Einstein-DVT evaluation. The primary efficacy objective is to evaluate whether rivaroxaban is at least as effective as enoxaparin/VKA in the treatment of patients with acute symptomatic deep-v...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

No Offene und multizentrische Studie bei Patienten mit Lungenhochdruck zum Überkreuzvergleich (Cross-over) von Verträglichkeit und Blutspiegeln von Iloprost (Ventavis) nach Inhalation von Ventavis mit dem Fox-Vernebler und dem I-Neb-Vernebler The primary objective of this study is to assess, in subjects with pulmonary arterial hypertension, the acute tolerability of 5 µg iloprost inhaled as Ventavis 20 µg/mL solution through a FOX nebulize...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO) To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on best-corrected visual acuity (BCVA) assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart in subjects...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

International, prospective, double-blind, 3-arm comparative, randomized, placebo controlled phase IV study on the effect of counseling and either tranexamic acid or mefenamic acid or placebo, on the management of bleeding/spotting in women using the levonorgestrel-releasing intrauterine system (MIRENA) for contraception To investigate if tranexamic acid and/or mefenamic acid are superior to placebo in the management of bleeding/spotting during the first 90 days of levonorgestrel-releasing intrauterine system use.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study with Riociguat (BAY 63-2521) in patients with pulmonary hypertension associated with left heart failure The primary objective of this study is to assess the hemodynamic profile of Riociguat in patients with symptomatic pulmonary hypertension associated with left ventricular systolic dysfunction (PH-sLVD...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Phase III study comparing Sorafenib to placebo in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens for advanced disease The objective of this phase III study is to compare the efficacy and safety of sorafenib monotherapy plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients with relapsed...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune